Facioscapulohumeral Muscular Dystrophy Market Gearing Up for Outstanding Expansion Across the 7MM During the Forecast Period (2025-2034)
LAS VEGAS, July 17, 2025 /PRNewswire/ — Facioscapulohumeral muscular dystrophy (FSHD) often starts with muscle weakness in the face, shoulders, and upper arms, and gradually progresses to affect the abdominal muscles, legs, and pelvic area as the disease advances. Symptoms commonly emerge during childhood or adolescence, though they can begin at any stage of life, from infancy to old age. There is considerable variation in symptom onset and severity, even among relatives with the condition.
Roughly 80% of individuals carrying the FSHD gene mutation experience symptoms, while the remaining 20% are asymptomatic, either showing no signs or only very mild symptoms that may go unnoticed until later in life. For FSHD1, children of an affected parent have a 50% likelihood of inheriting the disorder. In FSHD2, the inheritance risk depends on the genetic background of both parents, typically ranging from 25% to 50%.
In 2024, the United States represented about 45% of all FSHD cases across the 7MM, with numbers projected to rise by 2034. Most US patients in 2024 scored between 7 and 10 on the RICCI scale, indicating moderate to severe levels of muscle dysfunction.
Download the report to understand which factors are driving FSHD epidemiology trends @ Facioscapulohumeral Muscular Dystrophy Treatment Algorithm
At present, there are no available therapies that can slow, halt, or reverse the progression of muscle weakness in facioscapulohumeral muscular dystrophy. While physical therapy can be beneficial in some cases, it is generally recommended that individuals engage in regular low-resistance and aerobic exercise. Collaborating with a physical therapist is important to create a personalized and safe exercise regimen.
Some patients may benefit from surgical stabilization of the scapula to enhance their ability to raise their arms above shoulder level. Scapular fixation involves anchoring the shoulder blades to the ribs and may be performed on one or both sides. This is a complex procedure that should only be undertaken by skilled surgeons after thorough evaluation and discussion with both the surgeon and the neurologist. Additionally, medications such as NSAIDs, opioids, and antidepressants are commonly prescribed to manage FSHD-related pain.
Current care practices are centered around managing complications and preserving physical function. Rehabilitation consultations are advised for individuals facing mobility or functional issues. However, there remains a significant unmet need for effective and affordable approved therapies, as existing supportive treatments are often costly and limited in efficacy.
Learn more about the FSHD treatment @ New Treatment for Facioscapulohumeral Muscular Dystrophy
There remains a significant unmet need in the treatment of FSHD, as current approaches primarily involve off-label therapies. Management strategies are largely aimed at alleviating symptoms and preserving physical function. Although FSHD is a progressive disorder with potentially serious long-term effects, treatment options are still limited to symptomatic care.
Several investigational therapies are in development, including GYM329/RO7204239/RG6237 by Roche and Chugai Pharmaceutical, Delpacibart braxlosiran (del-brax) by Avidity Biosciences, EPI-321 by Epicrispr Biotechnologies, among others.
Discover which therapies are expected to grab major FSHD market share @ Facioscapulohumeral Muscular Dystrophy Market Report
GYM329 (also known as RO7204239 or RG6237) is an experimental anti-myostatin antibody aimed at enhancing skeletal muscle mass and growth. It has been specifically engineered as a 'recycling' and 'sweeping' antibody, meaning it may clear myostatin from the bloodstream more effectively than traditional antibodies. This targeted approach is expected to help address conditions marked by muscle wasting and reduced muscle strength. In November 2022, Roche began a Phase II clinical trial (NCT05548556) in patients with facioscapulohumeral muscular dystrophy, and according to the company, regulatory filing is anticipated after 2028.
As per Chugai Pharmaceutical's Q1 2025 update, results from the ongoing MANOEUVRE Phase II study for FSHD are expected in 2025. With proof of concept established, Chugai plans to advance to Phase III trials, set to begin in 2026.
Delpacibart braxlosiran (del-brax, formerly AOC 1020) is currently being assessed in the Phase I/II FORTITUDE trial (NCT06547216) in both adult and adolescent participants with FSHD. This study is focused on evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenously administered del-brax.
In June 2025, Avidity Biosciences announced that del-brax may qualify for an accelerated approval pathway in the U.S. for FSHD treatment. The company also launched the global Phase III FORWARD trial to serve as a confirmatory study for full regulatory approval. Additionally, Avidity reported positive topline results from the dose-escalation cohorts of the FORTITUDE trial, which will be shared at the 32nd Annual FSHD Society International Research Congress.
EPI-321 is an investigational, one-time gene-silencing therapy targeting abnormal DUX4 expression. Administered systemically via a validated AAV vector, EPI-321 has shown strong preclinical results, including effective suppression of DUX4 and preservation of muscle tissue. It has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA. The company is preparing to launch a global Phase I/II trial in 2025.
Discover more about drugs for FSHD in development @ Facioscapulohumeral Muscular Dystrophy Clinical Trials
The anticipated launch of these emerging therapies for FSHD are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the FSHD market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
DelveInsight estimates that the market size for FSHD is expected to grow at a significant CAGR by 2034. This growth is mainly driven by increased awareness, improved diagnostic techniques, and ongoing research into genetic therapies. Rising investment from pharmaceutical companies and the emergence of targeted therapies are expanding treatment options. Regulatory support for orphan diseases is also accelerating drug development.
DelveInsight's latest published market report, titled as Facioscapulohumeral Muscular Dystrophy Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the FSHD country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The FSHD market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalent Cases of FSHD
Total Diagnosed Prevalent Cases of FSHD
Type-specific Diagnosed Prevalent Cases of FSHD
Gender-specific Diagnosed Prevalent Cases of FSHD
Age-specific Diagnosed Prevalent Cases of FSHD
Severity-specific Diagnosed Prevalent Cases of FSHD
Total Treated Cases of FSHD
The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM FSHD market. Highlights include:
10-year Forecast
7MM Analysis
Epidemiology-based Market Forecasting
Historical and Forecasted Market Analysis upto 2034
Emerging Drug Market Uptake
Peak Sales Analysis
Key Cross Competition Analysis
Industry Expert's Opinion
Access and Reimbursement
Download this FSHD market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the FSHD market. Also, stay abreast of the mitigating factors to improve your market position in the FSHD therapeutic space.
Related Reports
Facioscapulohumeral Muscular Dystrophy Pipeline
Facioscapulohumeral Muscular Dystrophy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key FSHD companies, including Fulcrum Therapeutics, Dyne Therapeutics, Hoffmann-La Roche, aTyr Pharma, Inc., Avidity Biosciences, Inc., among others.
Facioscapulohumeral Muscular Dystrophy Epidemiology Forecast
Facioscapulohumeral Muscular Dystrophy Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted FSHD epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Duchenne Muscular Dystrophy Market
Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key DMD companies, including Sarepta Therapeutics, PTC Therapeutics, Nippon Shinyaku, Santhera Pharmaceuticals, ReveraGen BioPharma, Taiho Pharmaceutical, FibroGen, Capricor, Daiichi Sankyo, Italfarmaco, Antisense Therapeutics, Solid Biosciences, among others.
Spinal Muscular Atrophy Market
Spinal Muscular Atrophy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SMA companies, including Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Therapeutics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us Shruti Thakur info@delveinsight.com +14699457679
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/facioscapulohumeral-muscular-dystrophy-market-gearing-up-for-outstanding-expansion-across-the-7mm-during-the-forecast-period-20252034–delveinsight-302507691.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 days ago
- Malaysian Reserve
IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation
Breast surgeon, Professor Eisuke Fukuma, a highly regarded cryoablation expert & ProSense® user at Kameda Medical Center, presented updated breast cancer cryoablation data from an independent study of over 600 women from 2006 to 2023 Independent ProSense® study by Professor Hisanori Kawamoto demonstrating 0% breast cancer local recurrence wins Best of Breast Cancer Award Leading US Breast Surgeon, Dr. Richard Fine, presented data from IceCure's ICE3 study & discussed other recent publications on breast cancer cryoablation CAESAREA, Israel, July 25, 2025 /PRNewswire/ — IceCure Medical Ltd. (Nasdaq: ICCM) ('IceCure', 'IceCure Medical' or the 'Company'), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its participation in the 33rd Annual Meeting of the Japanese Breast Cancer Society's Conference (the 'Conference') which took place earlier this month in Tokyo. 'We believe ProSense® can make a significant impact on improving breast cancer outcomes in Japan by providing women with a minimally invasive option. This year's Conference was highly productive as we engaged with breast surgeons, thought leaders, and industry participants,' stated Eyal Shamir, IceCure's Chief Executive Officer. 'Working with Terumo Corporation in Japan, the country's largest medical device company, we anticipate strong commercial adoption upon regulatory approval for breast cancer, especially given the strong data coming from independent Japanese studies.' IceCure, a sponsor of the Conference, hosted a cryoablation-focused luncheon on Friday, July 11, 2025, led by Professor Takayuki Kinoshita, Division of Breast Surgery, NHO Tokyo Medical Center, with presentations made by: Professor Eisuke Fukuma, who has performed over 600 breast cryoablation procedures, the majority of which were conducted with ProSense®, presented the latest data from his ongoing activity to treat breast cancer at Kameda Medical Center. Professor Fukuma's presentation included the following: From June 2006 through December 2023, 535 breast cancer patients with tumor lesions of less than 15 millimeters and 76 patients with tumor lesions of less than 10 millimeters were treated. The overall ipsilateral breast tumor recurrence rate (IBTR') was 0.98% for up to 17 years, resulting in a 99.02% recurrence free rate. For a subpopulation with more than 10 years follow up, including 51 patients with invasive ductal carcinoma and 20 patients with ductal carcinoma in situ, the IBTR was 2.8%, resulting in a 97.2% recurrence free rate. From June 2006 through December 2023, 535 breast cancer patients with tumor lesions of less than 15 millimeters and 76 patients with tumor lesions of less than 10 millimeters were treated. The overall ipsilateral breast tumor recurrence rate (IBTR') was 0.98% for up to 17 years, resulting in a 99.02% recurrence free rate. For a subpopulation with more than 10 years follow up, including 51 patients with invasive ductal carcinoma and 20 patients with ductal carcinoma in situ, the IBTR was 2.8%, resulting in a 97.2% recurrence free rate. Dr. Richard Fine of West Cancer Center & Research Institute in the U.S., and a clinical investigator of IceCure's successfully completed ICE3 breast cancer clinical study, presented findings from the ICE3 study as well as data from independent studies of ProSense® in breast cancer. The Conference gave the Best of Breast Cancer award to an independent study published in the journal Breast Cancer titled 'Percutaneous ultrasound–guided cryoablation for early–stage primary breast cancer: a follow–up study in Japan'. This study was led by Professor Hisanori Kawamoto, M.D., Ph.D. from the Department of Breast Surgery, Breast and Imaging Center at St. Marianna University School of Medicine in Japan and reported zero (0%) breast cancer local recurrence 5 years following treatment with ProSense®. Dr. Kawamoto commented, 'This is a very important study in Japan, where we are experiencing an upward trend in breast cancer cases, especially among women in their late 40s to their early 60s. These are women who often are at very active stages of their life and therefore there is a growing demand for treatment options that minimize the chance of, or even avoid, hospitalization, in addition to resulting in favorable clinical and cosmetic outcomes. We are very pleased with these results and are hopeful that ProSense® may become a favored option in Japan upon regulatory approval for early-stage breast cancer.' Terumo Corporation is expected to submit an application to the Pharmaceuticals and Medical Devices Agency ('PMDA') of Japan for regulatory clearance for breast cancer indication for the ProSense® system by the end of 2025. About ProSense®The ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver. ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedures for breast tumors. About IceCure MedicalIceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia. Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the belief that ProSense® can make a significant impact on improving breast cancer outcomes in Japan; the Company's anticipation of strong commercial adoption upon regulatory approval of ProSense® for breast cancer; the belief of the importance of 'Percutaneous ultrasound–guided cryoablation for early–stage primary breast cancer: a follow–up study in Japan;' and that Terumo Corporation is expected to submit a PMDA application for regulatory clearance for breast cancer indication for the ProSense® system by the end of 2025. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. References and links to websites have been provided in this press release as a convenience, and the information contained on such websites is not incorporated by reference herein. IR Contact: Email: investors@ Michael Polyviou Phone: 732-232-6914 Logo – View original content:
Malaysian Reserve
2 days ago
- Malaysian Reserve
NAMI Statement on Executive Order Targeting Homelessness and Criminalizing Mental Illness
ARLINGTON, Va., July 25, 2025 /PRNewswire/ — Yesterday, the White House released a new Executive Order, 'Ending Crime and Disorder on America's Streets,' which directs federal agencies to make it easier to involuntarily treat people with serious mental illnesses as part of a bid to address homelessness across the United States. While addressing the nationwide homelessness crisis is urgent and necessary, yesterday's executive order promoting institutionalization of people with mental illness raises grave concerns for NAMI and our community. NAMI's Chief Executive Officer Daniel H. Gillison, Jr. said: 'Mental illness is not a crime, and people with mental illness deserve to be treated as human beings, with dignity and respect. While we agree that homelessness is an urgent crisis in our country, to truly address the systemic causes of this crisis, we should be pouring resources into treatment to improve early access to care and investing in supportive housing and other wrap-around services. It's always ideal – and best – for an individual to engage in their own treatment. Yet, too many NAMI families know that isn't always possible. Unfortunately, yesterday's order concerningly focuses broadly on institutionalization and not on real solutions that we know work in helping people lead better lives.' NAMI believes that in the rare instances where voluntary engagement in treatment is not possible, involuntary commitment should be used only as a last resort and only when it is believed to be in the best interests of the individual. While it is unclear how the executive order will be carried out since state law governs the process of involuntary civil commitment, the order also urges moving away from a 'housing first' approach, which has been successful in helping individuals stay connected to treatment and reduce homelessness. While NAMI is troubled by the overall order, it does include a direction to federal agencies to support crisis response services and prioritize funding for mental health and drug courts – strategies that NAMI supports. This executive order comes at a time when significant cuts are being made to mental health services nationwide. Earlier this month, Congress passed legislation that will drastically cut Medicaid and Supplemental Nutrition Assistance Program (SNAP) benefits, impacting millions of Americans. The Administration has rescinded more than $1 billion in grants from the Substance Abuse and Mental Health Services Administration (SAMHSA), with more cuts proposed for the next fiscal year. These changes will result in far too many people being unable to get the treatment they need. When that happens, more people will be arrested, incarcerated, land in emergency rooms, lose their connection to family and community, and ultimately become homeless. NAMI's Chief Advocacy Officer Hannah Wesolowski said: 'Rather than providing access to critical mental health services, this executive order appears to prioritize coercive tactics to move people who are homeless out of the public eye. This does nothing to address the root causes of homelessness, runs a high risk of exacerbating the homelessness crisis, and is not the way to address our mental health needs. People with mental illness deserve better.' For more information on the public policies that NAMI supports, visit
Malaysian Reserve
3 days ago
- Malaysian Reserve
Informal caregivers in Singapore seen as undertrained and overwhelmed
Despite nearly all professional caregivers agreeing that informal caregivers can help bridge the demand of caregiving in Singapore to a certain extent (30% large, 45% moderate, 23% small extent), only a quarter of professionals (25%) say that informal caregivers today are 'somewhat capable' of providing necessary care, with none believing they are 'very capable'. Around four in five (79%) professional caregivers say that informal caregivers are either 'minimally trained' or not 'trained at all' in caregiving; with all professionals agreeing (47% strongly agree, 53% agree) that informal caregivers should receive formal training, especially in skills such as basic emergency response (92%), proper lifting and transfer techniques (90%), recognising condition-specific warning signs and symptoms (88%). Nearly half of professional caregivers (47%) perceive that informal caregivers feel undervalued by society, employers, or even their own families, with a lack of respite care (92%), sleep deprivation (90%), and financial strain (85%) among the top personal challenges faced by informal caregivers. Singapore, July 25, 2025 /PRNewswire/ — Amidst the growing pressures of a super-aged society, Singapore's healthcare sector is experiencing a surge in caregiving demand. While all professional caregivers agree that informal caregivers, such as family members, foreign domestic workers, and volunteers, can help alleviate the demand of caregiving to a certain extent (30% large, 45% moderate, 23% small extent), there are concerns about their capability to provide effective care. Notably, a quarter of respondents (25%) consider informal caregivers only 'somewhat capable', with none believing that they are 'very capable'. This is further compounded by the widespread belief among professional caregivers that informal caregivers are undertrained (77% minimally trained, 2% not trained at all). Consequently, all of them agree (47% strongly agree, 53% agree) that informal caregivers should receive formal training. Essential skills identified by the professionals include basic emergency response (92%), proper lifting and transfer techniques (90%), recognising condition-specific warning signs and symptoms (88%), while important soft skills include decision-making (92%), adaptability (84%), and communication (83%). These are some of the key findings from NTUC LearningHub's Industry Insights Report 2025 on Caregiving, which investigates how professional caregivers, such as those working in the healthcare and social service sectors, perceive informal caregivers who provide support to individuals in need of care at home. Based on a survey of 200 professional caregivers, the report also explores the potential gaps in the caregiving landscape and the implications of evolving healthcare needs on informal caregivers. Additionally, the majority of professional caregivers (77%) also reveal that informal caregivers have little to no awareness of available resources and support services. The most common obstacles to providing effective care include a lack of medical and nursing knowledge (90%), time management (85%), and lack of access to proper equipment or assistive devices (81%). All professional caregivers agree (59% strongly agree, 41% agree) that there is an increasing demand for trained caregivers in Singapore, primarily driven by the ageing population and rising prevalence of chronic illnesses. In response to this growing need, all professional caregivers agree (30% large extent, 49% moderate extent, 22% small extent) that the adoption of assistive technologies has also helped to reduce the burden on informal caregivers, with the most helpful tools identified being mobility aids (97%), emergency response devices (92%) and smart home monitoring systems (82%). However, key barriers to adoption include a lack of training or guidance in effectively using assistive technology (91%), high cost of assistive technologies (91%), and technical complexity of using/setting up assistive tools (89%). At the same time, nearly half of professional caregivers (47%) believe that informal caregivers feel undervalued by society, employers, or even their families as they face personal challenges such as a lack of respite care (92%), sleep deprivation (90%) and financial strain (85%). Commenting on the report's findings, Mr Tay Ee Learn, Assistant Chief Executive Officer and Chief Sector Skills Officer, NTUC LearningHub, says, 'Demand for caregiving support is rising as Singapore's ageing population and the growing prevalence of chronic illnesses lead to longer-term and more complex care needs. Beyond professional caregivers, informal caregivers are quietly but surely cementing their role as key contributors in the care economy, providing invaluable day-to-day care. It is therefore important that they are given access to formal training and relevant resources as they often take on complex caregiving responsibilities without prior experience or professional guidance. With proper training and support, informal caregivers can be empowered to deliver safer, more effective and quality care for their loved ones without compromising their personal well-being. Ultimately, formal training also leads to certifications, providing opportunities for informal caregivers to become professionals in the healthcare sector.' To download the Industry Insights Report 2025 on Caregiving, please visit To find out more about the courses, training, and grants, please contact NTUC LearningHub at About NTUC LearningHub NTUC LearningHub is the leading Continuing Education and Training provider in Singapore which aims to transform the lifelong employability of working people. Since our corporatisation in 2004, we have been working with employers and individual learners to provide learning solutions in areas such as Infocomm Technology, Generative AI & Cloud, Healthcare, Retail & Food Services, Employability & Literacy, Business Excellence, Workplace Safety & Health, Security, Human Resources & Coaching and Foreign Workers Training. To date, NTUC LearningHub has helped over 34,000 organisations and achieved more than 3.2 million training places across more than 1,000 courses with a pool of about 1,000 certified trainers. As a Total Learning Solutions provider to organisations, we also forge partnerships to offer a wide range of relevant end-to-end training. Besides in-person training, we also offer instructor-led virtual live classes (VLCs) and asynchronous online learning. The NTUC LearningHub Learning eXperience Platform (LXP) — a one-stop online learning platform — offers timely, bite-sized and quality content for learners to upskill anytime and anywhere. Beyond learning, LXP also serves as a platform for jobs and skills development for both workers and companies. For more information, visit
